EQUASENS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.1 EUR | -1.36% |
|
-4.75% | -4.91% |
| Apr. 02 | Equasens : RNPG virtually stable in 2023 | CF |
| Mar. 29 | Equasens Société Anonyme Provides Revenue Guidance for the 2025 | CI |
| Sales 2023 | 220M 234M | Sales 2024 * | 231M 247M | Capitalization | 873M 930M |
|---|---|---|---|---|---|
| Net income 2023 | 47M 50.07M | Net income 2024 * | 49M 52.2M | EV / Sales 2023 | 4.18 x |
| Net cash position 2023 * | 35.92M 38.27M | Net cash position 2024 * | 64.17M 68.35M | EV / Sales 2024 * | 3.5 x |
| P/E ratio 2023 |
19.5
x | P/E ratio 2024 * |
17.4
x | Employees | - |
| Yield 2023 * |
2.09% | Yield 2024 * |
2.29% | Free-Float | 32.43% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.36% | ||
| 1 week | -4.75% | ||
| Current month | +13.26% | ||
| 1 month | +16.43% | ||
| 3 months | +2.47% | ||
| 6 months | -8.50% | ||
| Current year | -4.91% |
1 week
57.00
61.30
1 month
50.0061.80
Current year
46.1561.80
1 year
46.1585.80
3 years
46.15103.00
5 years
41.25124.20
10 years
17.43124.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 90-12-31 | |
Thierry Chapusot
FOU | Founder | 65 | 96-01-24 |
| Director of Finance/CFO | - | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thierry Chapusot
FOU | Founder | 65 | 96-01-24 |
| Director/Board Member | 46 | 17-06-26 | |
| Director/Board Member | 59 | 99-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 58.1 | -1.36% | 8,245 |
| 24-04-18 | 58.9 | +0.17% | 11,556 |
| 24-04-17 | 58.8 | +1.20% | 5,928 |
| 24-04-16 | 58.1 | -3.17% | 12,904 |
| 24-04-15 | 60 | -1.64% | 14,345 |
Real-time Euronext Paris, April 19, 2024 at 11:35 am EDT
More quotes
Equasens is No. 1 in France for publishing and integrating software programs for pharmacies, hospitals, healthcare facilities, laboratories, retirement homes and healthcare professionals. Net sales break down by activity as follows:
- pharmacy software publishing and integration (73%): software programs for managing data bases, information, inventories, orders, electronic care records, etc.;
- publishing of IT solutions for health and medical/social establishments (15.2%): publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, billing, receipt and accounting management, care management, supply management, etc.);
- development of solutions and infrastructures for e-Health (11.8%): digital communication, telemedicine and telehealth solutions. The group also offers financing solutions for leased goods (Nanceo).
Net sales are distributed geographically as follows: France (90.9%), Italy (4.9%), Belgium and Luxembourg (2.7%), Ireland and the United Kingdom (0.8%) and Germany (0.7%).
Sector
IT Services & Consulting
Calendar
2024-05-06
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
58.1
EUR
Average target price
71.25
EUR
Spread / Average Target
+22.63%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.91% | 932M | |
| -9.70% | 199B | |
| +0.86% | 166B | |
| +11.02% | 166B | |
| +4.44% | 99.95B | |
| +6.17% | 76.71B | |
| +10.70% | 68.36B | |
| -8.53% | 70.07B | |
| -26.91% | 48.57B | |
| -1.27% | 47.01B |
- Stock Market
- Equities
- EQS Stock
